Clinical Trials and Role of Clobazam Reviewed in New Article

Writing in Medscape News Today, Andrew N. Wilner, MD, reviews the process whereby the U. S. Food and Drug Administration (FDA) approved clobazam (in the form of tablets under the brand name ONFI) as an orphan drug for use in treating Lenn... Learn More

SCN1A Mutation Affects Circadian Rhythms in Dravet Patients, Researchers Find

A team of researchers at the University of Washington believe that they have found the reason that people with Dravet syndrome experience sleep disorders. They have found that mice with a heterozygous loss-of-function mutation in the SCN1A gene --... Learn More

ONFI (Clobazam) Tablets Now Available at U.S. Retail Pharmacies

As of January 3, the oral antiepileptic drug ONFI (clobazam) is available in tablet form by prescription in the United States, according to its manufacturer, Lundbeck. Late last year, the FDA approved ONFI for the adjunctive treatment of seizures ... Learn More

GEFS+ Phenotypes Identified in Study

A recent study from the UK has identified four broad phenotypes (set of observable characteristics) of generalized epilepsy with febrile seizures plus (GEFS+). The study, which looked at 80 families, divided the manifestations of GEFS+ into the fo... Learn More

Nocturnal Seizures May Indicate Higher SUDEP Risk, Study Finds

A recent study of deaths caused by sudden unexpected death in epilepsy (SUDEP) has found that people with sleep-related SUDEP were more likely to have had a history of nocturnal seizures than those whose SUDEP was not related to sleep.

The s... Learn More